The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease
© 2022. The Author(s)..
Dysregulation of nicotinamide adenine dinucleotide (NAD +) metabolism contributes to the initiation and progression of age-associated diseases, including chronic kidney disease (CKD). Nicotinamide N-methyltransferase (NNMT), a nicotinamide (NAM) metabolizing enzyme, regulates both NAD + and methionine metabolism. Although NNMT is expressed abundantly in the kidney, its role in CKD and renal fibrosis remains unclear. We generated NNMT-deficient mice and a unilateral ureter obstruction (UUO) model and conducted two clinical studies on human CKD to investigate the role of NNMT in CKD and fibrosis. In UUO, renal NNMT expression and the degraded metabolites of NAM increased, while NAD + and NAD + precursors decreased. NNMT deficiency ameliorated renal fibrosis; mechanistically, it (1) increased the DNA methylation of connective tissue growth factor (CTGF), and (2) improved renal inflammation by increasing renal NAD + and Sirt1 and decreasing NF-κB acetylation. In humans, along with CKD progression, a trend toward a decrease in serum NAD + precursors was observed, while the final NAD + metabolites were accumulated, and the level of eGFR was an independent variable for serum NAM. In addition, NNMT was highly expressed in fibrotic areas of human kidney tissues. In conclusion, increased renal NNMT expression induces NAD + and methionine metabolism perturbation and contributes to renal fibrosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Scientific reports - 12(2022), 1 vom: 16. Apr., Seite 6398 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Takahashi, Rina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0U46U6E8UK |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 16.07.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-022-10476-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339600519 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339600519 | ||
| 003 | DE-627 | ||
| 005 | 20231226204521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-022-10476-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339600519 | ||
| 035 | |a (NLM)35430611 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Takahashi, Rina |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Dysregulation of nicotinamide adenine dinucleotide (NAD +) metabolism contributes to the initiation and progression of age-associated diseases, including chronic kidney disease (CKD). Nicotinamide N-methyltransferase (NNMT), a nicotinamide (NAM) metabolizing enzyme, regulates both NAD + and methionine metabolism. Although NNMT is expressed abundantly in the kidney, its role in CKD and renal fibrosis remains unclear. We generated NNMT-deficient mice and a unilateral ureter obstruction (UUO) model and conducted two clinical studies on human CKD to investigate the role of NNMT in CKD and fibrosis. In UUO, renal NNMT expression and the degraded metabolites of NAM increased, while NAD + and NAD + precursors decreased. NNMT deficiency ameliorated renal fibrosis; mechanistically, it (1) increased the DNA methylation of connective tissue growth factor (CTGF), and (2) improved renal inflammation by increasing renal NAD + and Sirt1 and decreasing NF-κB acetylation. In humans, along with CKD progression, a trend toward a decrease in serum NAD + precursors was observed, while the final NAD + metabolites were accumulated, and the level of eGFR was an independent variable for serum NAM. In addition, NNMT was highly expressed in fibrotic areas of human kidney tissues. In conclusion, increased renal NNMT expression induces NAD + and methionine metabolism perturbation and contributes to renal fibrosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a NAD |2 NLM | |
| 650 | 7 | |a 0U46U6E8UK |2 NLM | |
| 650 | 7 | |a Niacinamide |2 NLM | |
| 650 | 7 | |a 25X51I8RD4 |2 NLM | |
| 650 | 7 | |a Methionine |2 NLM | |
| 650 | 7 | |a AE28F7PNPL |2 NLM | |
| 650 | 7 | |a Nicotinamide N-Methyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.1.1.1 |2 NLM | |
| 700 | 1 | |a Kanda, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Komatsu, Motoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Itoh, Tomoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Minakuchi, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Urai, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Kuroita, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Shigaki, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Tsukamoto, Tasuku |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, Naoko |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Minoru |e verfasserin |4 aut | |
| 700 | 1 | |a Yamanaka, Risa |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimura, Norito |e verfasserin |4 aut | |
| 700 | 1 | |a Ono, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Yukioka, Hideo |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tokuyama, Hirobumi |e verfasserin |4 aut | |
| 700 | 1 | |a Wakino, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Itoh, Hiroshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 12(2022), 1 vom: 16. Apr., Seite 6398 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:16 |g month:04 |g pages:6398 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-022-10476-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 16 |c 04 |h 6398 | ||